ANNOUNCEMENT NO. 233
14 December 2022
Management change
Steen Søndergaard has announced that he wants to resign from his position as CEO of ChemoMetec A/S.
It has been agreed that Steen Søndergaard remains in his position until a replacement has been found, however with resignation during the calendar year 2023 and possibly no later than 30 June 2023.
The search for a new CEO has been initiated, and the Board of Directors expects to announce the name of the new CEO during the first quarter of 2023.
For further information
Niels Thestrup, Chairman of the Board, ChemoMetec A/S
Phone: (+45) 3370 2000
About ChemoMetec A/S
ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies, such as Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson.
ChemoMetec was founded in 1997 and is listed on the Nasdaq Copenhagen stock exchange. For more information, go to www.chemometec.com
Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at…
LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…
Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…
Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…
Independent analysis examines why 'natural Ozempic alternative' and 'berberine weight loss patch' searches are driving…